sefaxersen Updated Oct 23
The Phase 3 success is a major derisking event, but the stock hasn't rallied, watch for regulatory submission timing from Roche and the week 105 eGFR data, which will determine the full approval path. The stock near its 52-week low with strong analyst support and a deep pipeline (bepirovirsen/HIBSAGO just approved, zilganersen PDUFA passed) creates an asymmetric risk/reward for investors willing to wait for regulatory milestones.
- Phase 3 IMAgINATION study met primary endpoint with a highly significant 43.1% reduction in proteinuria vs placebo (P<0.0001), a strong efficacy signal that positions sefaxersen as potentially best-in-class for IgAN
- Clean safety profile with no new safety signals, consistent with Phase 2, a key differentiator versus some competitors with boxed warnings
- Roche is a deep-pocketed partner committed to regulatory submission, providing development and commercialization firepower
- Regulatory approval is not guaranteed, the FDA may require additional data, particularly the week 105 eGFR data showing long-term kidney function benefit, before approving
- Competition from approved IgAN therapies like Tarpeyo (budesonide) and Filspari (sparsentan) could limit market share and pricing power
- Stock is trading near its 52-week low (~$42.93 vs 52-week high of $86.74), suggesting the market may have already priced in positive Phase 3 results or has other concerns about Ionis